The correlation of cortactin and fascin-1 expression with clinicopathological parameters in pancreatic and ampulla of Vater adenocarcinoma

APMIS

Volumn 121, Issue 3, 2013, Pages 171-181

  Tsai, Wen Chiuan ^a   Lin, Chih Kung ^a   Lee, Herng Sheng ^a   Gao, Hong Wei ^a   Nieh, Shin ^a   Chan, De Chuan ^a   Jin, Jong Shiaw ^b  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b TUNGS' TAICHUNG METROHARBOR HOSPITAL   (Taiwan)

Author keywords

Cortactin; Fascin; Immunostaining; Pancreatic adenocarcinoma

Indexed keywords

CORTACTIN; FASCIN; PROTEIN FASCIN 1; UNCLASSIFIED DRUG;

ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL TIME; TUMOR DIFFERENTIATION; VATER PAPILLA ADENOCARCINOMA; VATER PAPILLA CARCINOMA;

ADENOCARCINOMA; AMPULLA OF VATER; CARRIER PROTEINS; COMMON BILE DUCT NEOPLASMS; CORTACTIN; DUODENAL NEOPLASMS; FEMALE; GENE EXPRESSION; HUMANS; MALE; MICROFILAMENT PROTEINS; PANCREATIC NEOPLASMS; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84874189334     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2012.02952.x     Document Type: Article

References (43)

1. Chu PG, Schwarz RE, Lau SK, Yen Y, Weiss LM. Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma. Am J Surg Pathol 2005;29:359-67.
2. Bosman FT, Carneiro F, Hruban RH, Theise ND. World Health Organization Classification of Tumours of the Digestive system. Lyon: IARC Press, 2000.
3. Yeo CJ, Cameron JL, Lillemoe KD, Sitzmann JV, Hruban RH, Goodman SN, et al. Pancreaticoduodenectomy for cancer of the head of the pancreas: 201 patients. Ann Surg 1995;221:721-31.
4. Trede M, Schwall G, Saeger HD. Survival after pancreatoduodenectomy. 118 consecutive resections without an operative mortality. Ann Surg 1990;211:447-58.
5. Furukawa T, Takahashi T, Kobari M, Matsuno S. The mucus-hypersecreting tumor of the pancreas. Development and extension visualized by three-dimensional computerized mapping. Cancer 1992;70:1505-13.
6. Tsuchiya R, Noda T, Harada N, Miyamoto T, Tomioka T, Yamamoto K, et al. Collective review of small carcinomas of the pancreas. Ann Surg 1986;203:77-81.
7. Tsunoda T, Ura K, Eto T, Matsumoto T, Tsuchiya R. UICC and Japanese stage classifications for carcinoma of the pancreas. Int J Pancreatol 1991;8:205-14.
8. Wasif N, Ko CY, Farrell J, Wainberg Z, Hines OJ, Reber H, et al. Impact of tumor grade on prognosis in pancreatic cancer: should we include grade in AJCC staging? Ann Surg Oncol 2010;17:2312-20.
9. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, et al. AJCC Cancer Staging Manual. 7th edn, New York, NY: Springer, 2010.
10. Howe JR, Klimstra DS, Moccia RD, Conlon KC, Brennan MF. Factors predictive of survival in ampullary carcinoma. Ann Surg 1998;228:87-94.
11. Charcton B, Coiffic J, Landen S, Bardaxoglou E, Campion JP, Launois B. Diagnosis and therapy for ampullary tumors: 63 cases. World J Surg 1996;20:707-12.
12. Allema JH, Reinders ME, van Gulik TM, van Leeuwen DJ, Verbeek PC, de Wit LT, et al. Results of pancreaticoduodenectomy for ampullary carcinoma and analysis of prognostic factors for survival. Surgery 1995;117:247-53.
13. Van Heek NT, Maitra A, Koopmann J, Fedarko N, Jain A, Rahman A, et al. Gene expression profiling identifies markers of ampullary adenocarcinoma. Cancer Biol Ther 2004;3:651-6.
14. Luo ML, Sakuragi N, Shimizu M, Seino K, Okamoto K, Kaneuchi M, et al. Amplification and overexpression of CTTN (EMS1) contribute to the metastasis of esophageal squamous cell carcinoma by promoting cell migration and anoikis resistance. Cancer Res 2006;66:11690-9.
15. van Rossum AG, Schuuring-Scholtes E, van Buuren-van Seggelen V, Kluin PM, Schuuring E. Comparative genome analysis of cortactin and HS1: the significance of the F-actin binding repeat domain. BMC Genomics 2005;6:15.
16. Weed SA, Parsons JT. Cortactin: coupling membrane dynamics to cortical actin assembly. Oncogene 2001;20:6418-34.
17. Daly RJ. Cortactin signalling and dynamic actin networks. Biochem J 2004;382:13-25.
18. Greer RO Jr, Said S, Shroyer KR, Marileila VG, Weed SA. Overexpression of cyclin D1 and cortactin is primarily independent of gene amplification in salivary gland adenoid cystic carcinoma. Oral Oncol 2007;43:735-41.
19. Rothschild BL, Shim AH, Ammer AG, Kelley LC, Irby KB, Head JA, et al. Cortactin overexpression regulates actin-related protein 2/3 complex activity, motility, and invasion in carcinomas with chromosome 11q13 amplification. Cancer Res 2006;66:8017-25.
20. Tsai WC, Jin JS, Chang WK, Chan DC, Yeh MK, Cherng SC, et al. Association of cortactin and fascin-1 expression in gastric adenocarcinoma: correlation with clinicopathological parameters. J Histochem Cytochem 2007;55:955-62.
21. Adams JC. Roles of fascin in cell adhesion and motility. Curr Opin Cell Biol 2004;16:590-96.
22. Kureishy N, Sapountzi V, Prag S, Anilkumar N, Adams JC. Fascins, and their roles in cell structure and function. BioEssays 2002;24:350-61.
23. Adams JC. Fascin protrusions in cell interactions. Trends Cardiovasc Med 2004;14:221-6.
24. Hashimoto Y, Shimada Y, Kawamura J, Yamasaki S, Imamura M. The prognostic relevance of fascin expression in human gastric carcinoma. Oncology 2004;67:262-270.
25. Tsai WC, Sheu LF, Nieh S, Yu CP, Sun GH, Lin YF, et al. Association of EMMPRIN and fascin expression in renal cell carcinoma: correlation with clinicopathological parameters. World J Urol 2007;25:73-80.
26. Tsai WC, Chao YC, Sheu LF, Chang JL, Nieh S, Jin JS. Overexpression of fascin-1 in advanced colorectal adenocarcinoma: tissue microarray analysis of immunostaining scores with clinicopathological parameters. Dis Markers 2007;23:153-60.
27. Tsai WC, Chao YC, Sheu LF, Lin YF, Nieh S, Chen A, et al. EMMPRIN and fascin overexpression associated with clinicopathologic parameters of pancreatobiliary adenocarcinoma in Chinese people. APMIS 2007;115:929-38.
28. Zhou H, Schaefer N, Wolff M, Fischer HP. Carcinoma of the ampulla of Vater: comparative histologic/immunohistochemical classification and follow-up. Am J Surg Pathol 2004;28:875-82.
29. Swierczynski SL, Maitra A, Abraham SC, Iacobuzio-Donahue CA, Ashfaq R, Cameron JL, et al. Analysis of novel tumor markers in pancreatic and biliary carcinomas using tissue microarrays. Hum Pathol 2004;35:357-66.
30. van Rossum AG, Moolenaar WH, Schuuring E. Cortactin affects cell migration by regulating intercellular adhesion and cell spreading. Exp Cell Res 2006;312:1658-70.
31. Ormandy CJ, Musgrove EA, Hui R, Daly RJ, Sutherland RL. Cyclin D1, EMS1 and 11q13 amplification in breast cancer. Breast Cancer Res Treat 2003;78:323-35.
32. Schuuring E. The involvement of the chromosome 11q13 region in human malignancies: cyclin D1 and EMS1 are two new candidate oncogenes-a review. Gene 1995;159:83-96.
33. Schuuring E, Verhoeven E, van Tinteren H, Peterse JL, Nunnink B, Thunnissen FB, et al. Amplification of genes within the chromosome 11q13 region is indicative of poor prognosis in patients with operable breast cancer. Cancer Res 1992;52:5229-34.
34. Hashimoto Y, Skacel M, Adams JC. Roles of fascin in human carcinoma motility and signaling: prospects for a novel biomarker? Int J Biochem Cell Biol 2005;37:1787-804.
35. Edwards RA, Bryan J. Fascins, a family of actin bundling proteins. Cell Motil Cytoskeleton 1995;32:1-9.
36. De Arcangelis A, Georges-Labouesse E, Adams JC. Expression of fascin-1, the gene encoding the actin-bundling protein fascin-1, during mouse embryogenesis. Gene Expr Patterns 2004;4:637-43.
37. Tubb B, Mulholland DJ, Vogl W, Lan ZJ, Niederberger C, Cooney A, et al. Testis fascin (FSCN3): a novel paralog of the actin-bundling protein fascin expressed specifically in the elongate spermatid head. Exp Cell Res 2002;275:92-109.
38. Grothey A, Hashizume R, Sahin AA, McCrea PD. Fascin, an actin-bundling protein associated with cell motility, is upregulated in hormone receptor negative breast cancer. Br J Cancer 2000;83:870-3.
39. Roma AA, Prayson RA. Fascin expression in 90 patients with glioblastoma multiforme. Ann Diagn Pathol 2005;9:307-11.
40. Xie JJ, Xu LY, Zhang HH, Cai WJ, Mai RQ, Xie YM, et al. Role of fascin in the proliferation and invasiveness of esophageal carcinoma cells. Biochem Biophys Res Commun 2005;337:355-62.
41. Pelosi G, Pastorino U, Pasini F, Maissoneuve P, Fraggetta F, Iannucci A, et al. Independent prognostic value of fascin immunoreactivity in stage I nonsmall cell lung cancer. Br J Cancer 2003;88:537-47.
42. Tong GX, Yee H, Chiriboga L, Hernandez O, Waisman J. Fascin-1 expression in papillary and invasive urothelial carcinomas of the urinary bladder. Hum Pathol 2005;36:741-6.
43. Fan G, Kotylo P, Neiman RS, Braziel RM. Comparison of fascin expression in anaplastic large cell lymphoma and Hodgkin disease. Am J Clin Pathol 2003;119:199-204.